About US
Contact us
-
Not so fast, Endo and Allergan: Ohio's AG is looking past your opioid dealsWith national opioid litigation heating up, Endo and Allergan saw an off-ramp and took it, agreeing to settle with two Ohio counties for a combined $16 million this week. But the state'sattorney gene2019/8/21
-
2-month HIV injection could be on its way, as ViiV touts new dual-drug winImagine HIV patients needed to take their antiretroviral therapies not every day, not even every month, but every two months. A GlaxoSmithKline two-drug injectable regimen that’s already under review2019/8/21
-
AstraZeneca and FibroGen's roxadustat, not yet filed in U.S., nabs 2nd anemia nod in ChinaFibroGen has not even filed its AstraZeneca-partnered oral anemia drug roxadustat forU.S. approval. But the collaborators have already scored theirsecond nod for the blockbuster hopeful in China. Las2019/8/20
-
Enough hubbub about HHS' Truvada patents, Gilead says. We're challenging them at the PTODrugmakershave often lambasted the U.S. Patent and Trademark Office’s (PTO's) interpartesreview system, but now Gilead Sciences is hoping to use it to its advantage. Thedrugmakeristaking onthe U.S. g2019/8/20
-
Dillon, who shaped NICE into an influential gatekeeper, ready to exit CEO postTwenty years after its founding, England’s National Institute for Health and Care Excellence (NICE) has established itself as perhaps the world’s preeminent drug cost watchdog. Now, the only leader i2019/8/19
-
Roche's Hemlibra scores funding to treat much larger group of patients in EnglandRoche’sHemlibrahas been storming out of the gate since its first approval in 2017. Now, it's set to benefit a much wider patient group in England thanks to new funding from health authorities there.2019/8/19
-
Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasisEli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis. Taltz met the p2019/8/16
-
CureVac and Yale University to develop mRNA-based lung therapiesBiopharmaceutical firm CureVac has signed a collaborative research agreement with US-based Yale University to discover new therapeutic candidates for the treatment of pulmonary diseases. The partners2019/8/15
-
AstraZeneca announces breakthrough therapy status for Calquence in CLLAstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL). The i2019/8/15
-
Boehringer partners with MD Anderson on virtual R&D centreBoehringer Ingelheim has collaborated with The University of Texas MD Anderson Cancer Center to create a joint Virtual Research and Development Center focused on oncology research. The new initiative2019/8/14